Is Vertex Pharmaceuticals (VRTX) a risky stock?
As of July 21, 2026, Clavix grades Vertex Pharmaceuticals (VRTX) B+ for risk, a composite score of 78 out of 100 on an A+ to F scale, which puts VRTX in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind VRTX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how VRTX scores on each, as of July 21, 2026.
What's moving VRTX's risk right now
Company-specific signals Clavix flags behind VRTX's current grade, drawn from recent news and filings as of July 21, 2026.
Vertex is deploying $10B in capital to diversify its revenue base away from cystic fibrosis dependence, signaling a strategic pivot toward endocrine therapeutics that could reshap…
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
What a B+ grade means
On the Clavix A+ to F scale, VRTX's composite of 78 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell VRTX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.